lifestyle.pspl.com

Author: Cue Biopharma, Inc.

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

May 6, 2026
Cue Biopharma Announces $30 Million Private Placement

May 6, 2026
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

May 6, 2026
Cue Biopharma Announces 1-for-30 Reverse Stock Split

May 5, 2026
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

May 4, 2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

May 3, 2026
Cue Biopharma Announces CEO Transition

May 2, 2026
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

May 2, 2026
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

May 2, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

April 30, 2026